// App-Quantinova.ai

715 : FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action

Researchers

Presenter

  • Michelle Morrow

Principal Investigators

  • Mustapha Faroudi

  • Krishnendu Chakraborty

  • Wenjia Liao

  • Julia Winnewisser

  • Claire Seal

  • Daniel Gliddon

  • Neil Brewis

Medical Centers

  • F-Star Biotechnology Ltd, Cambrige, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • FS118

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved